Lyme borreliosis - A review of the late stages and treatment of four cases

Acta Clinica Belgica

Volumn 53, Issue 3, 1998, Pages 178-183

  Petrovic, M ^a   Vogelaers, D ^a   Van Renterghem, L ^a   Carton, D ^a   De Reuck, J ^a   Afschrift, M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME; DOXYCYCLINE FOSFATEX; MINOCYCLINE; PENICILLIN V; PROBENECID; VACCINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYME DISEASE; MALE; MENINGOENCEPHALITIS; POLYRADICULITIS; SCHOOL CHILD; SEROLOGY;

EID: 0031821547     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754160     Document Type: Article

References (22)

1. Steere AC. Borrelia burgdorferi (Lyme disease, Lyme borreliosis). In: Mandel GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. New York: Churchill Livingstone Inc. 1995: 2143-55.
2. Burgdorfer W, Barbour AG, Hayes SF et al. Lyme disease: a tick borne spirochetosis? Science. 1982; 216: 1317-9.
3. Goubau P, Bigaignon G. Lyme borreliosis - the new face of an old disease. Acta Clin Belg. 1987; 42: 1-4.
4. Bigaignon G, Tomasi JP, Goubau P et al. A clinical and sero-epidemiological study of 190 Belgian patients suffering from Lyme borreliosis. Acta Clin Belg. 1989; 44: 175-81.
5. Pfister HW, Weber K. Lyme Borreliosis. Basel: Editions Roche. 1990: 7-32.
6. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppälä. Treatment of late Lyme borreliosis. J Inf. 1994; 29: 255-61.
7. O'Connell S. Lyme disease in the United Kingdom. BMJ. 1995; 310: 303-8.
8. Steere AC. Lyme disease. N Engl J Med. 1989; 321: 586-96.
9. Reik L. Lyme disease and the nervous system. New York: Thieme Medical Publishers Inc. 1991: 55.
10. Herskowitz S, Berger A, Szwerdlow ML. Guillain-Barré syndrome associated with Lyme borreliosis. Neurology. 1990; 40 (suppl 1): 342.
11. Bouma PAD, Carpay HA. Antibodies to Borrelia burgdorferi in Guillain-Barré syndrome. Lancet. 1989; 2: 739.
12. Dam EP, Jonker DR, Hoorntje JCA. Temporary decrease in heart rate in Lyme carditis during treatment with antibiotics. Heart. 1996; 76: 289-90.
13. Wilske B, Preac-Mursic V, Göbel UB et al. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and Osp A sequence analysis. J Clin Microbiol. 1993; 31: 340-50.
14. Wilske B, Fingerle V, Herzer P et al. Recombinant immunoblot in the serodiagnosis of Lyme borreliosis - comparison with indirect immunofluorescence and enzyme-linked immunosorbent assay. Med Microbiol Immunol. 1993; 182: 255-70.
15. Strle F, Nelson JA, Ruzic-Sabljic E et al. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Inf Dis. 1996; 23: 61-5.
16. Aguero-Rosenfeld ME, Nowakowski J, Bittker S et al. Evolution of serologic response to Borrelia burg-dorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol. 1996; 34: 1-9.
17. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in Southeastern Connecticut. N Engl J Med. 1996; 335: 1270-4.
18. Report on WHO workshop on Lyme borreliosis diagnosis and surveillance. Warsaw, Poland, June 20-22 1995, S. Tylewska-Wierzbanowska (ed.) - Natl. Inst. Hygiene, Warsaw, Poland. WHO/CDS/VHP/95, 141-1.
19. Stanek G, O'Connell S, Cimmino M et al. European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr. 1996; 108: 741-7.
20. Stiernstedt G. Therapeutic options on Lyme borreliosis. Ann Rheum Dis. 1993; 52: 387-412.
21. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med. 1991; 114: 472-80.
22. Wilske B, Busch U, Fingerle V et al. Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development. Infection. 1996; 24: 208-12.